Immunomodulation in multiple sclerosis

Multiple sclerosis (MS) represents the prototypic inflammatory autoimmune disorder of the central nervous system and is the most common cause of neurological disability in young adults. The mainstays in the immunomodulatory therapy of MS are currently interferon beta and glatiramer acetate, both of which have proven to be clinically and paraclinically effective. Current clinical evidence indicates that treatment should be initiated as early as possible. In this review, we summarize available data from clinical studies on the clinical efficacy of immunomodulatory drugs for the treatment of patients with multiple sclerosis.